Brazil SUS Medical Device Procurement: Public Healthcare System Market Access Guide (2026)

Why Understanding Brazil's SUS Medical Device Procurement Matters

Brazil operates the world's largest public healthcare system by population coverage. The Sistema Unico de Saude (SUS) serves over 215 million people and is constitutionally mandated to provide universal, free healthcare. The system encompasses more than 50,000 clinics and hospitals across 5,568 municipalities and 27 states. For medical device manufacturers, SUS represents a procurement ecosystem of extraordinary scale -- but one with complex, multi-layered rules that differ fundamentally from private-sector or single-payer systems found elsewhere.

Yet many international manufacturers focus exclusively on obtaining ANVISA registration and building private-sector distribution, treating the public procurement channel as an afterthought. This is a significant strategic error. While the private sector accounts for approximately 68% of device purchases in Brazil, the public system spends tens of billions annually and represents the primary route to reach the majority of the Brazilian population. Understanding SUS procurement -- from the legal framework and e-procurement platforms to CONITEC health technology assessment and pricing mechanisms -- is essential for any manufacturer seeking comprehensive market penetration in Brazil.

This guide covers the full SUS medical device procurement landscape: the institutional architecture, the legal framework that governs all public purchasing, how CONITEC evaluates technologies for SUS incorporation, the e-procurement process and platforms, pricing and reimbursement mechanisms, requirements specific to foreign suppliers, SUS digital transformation initiatives, and practical strategies for market entry.

Brazil's Healthcare System Overview

SUS: A Constitutionally Mandated Universal System

The Sistema Unico de Saude was established by the 1988 Brazilian Constitution (Articles 196-200) and is governed by the principles of universality, equity, and comprehensiveness. Unlike many universal healthcare systems that evolved incrementally, SUS was created as a constitutional right: every person present in Brazil -- citizen or foreign national, employed or unemployed -- is entitled to healthcare through SUS at no point of service.

SUS is funded through general taxation (social security contributions, federal budget allocations, state and municipal health budgets) and organized as a decentralized system where the federal government sets national policy and provides funding, while states and municipalities are responsible for service delivery and procurement.

Key Market Data

Metric	Value
Population covered by SUS	215+ million
SUS annual spending on medicines (2026)	~$75 billion
Brazilian medical device market	~$10-12 billion
Private sector share of device purchases	~68%
Public sector share of device purchases	~32%
SUS facilities (clinics and hospitals)	50,000+
Number of municipalities	5,568
Number of states	26 + Federal District
Brazilians reporting unmet treatment needs	~15 million

Systemic Challenges

Despite its scale, SUS faces persistent challenges. Approximately 15 million Brazilians report not receiving treatment they need, with gaps most acute in specialist care, diagnostic imaging, and high-complexity procedures. Regional disparities are significant: the more rural northern and northeastern regions pay more for essential medicines despite lower per capita income, reflecting logistical costs and weaker procurement capacity at the municipal level. These disparities have direct implications for device manufacturers -- products that succeed in Sao Paulo or Rio de Janeiro may face very different demand patterns and procurement processes in Para or Maranhao.

Key Institutions Governing Medical Device Procurement

Institution	Role	Relevance to Device Manufacturers
SUS (Sistema Unico de Saude)	Unified public health system	Primary public purchaser; sets clinical needs
ANVISA	National health surveillance agency	Device regulation, registration, Classes I-IV
CONITEC	National HTA commission	Evaluates technologies for SUS incorporation
Ministry of Health	Federal health authority	Oversees SUS, sets policy, manages national tenders
CMED	Drug price regulation chamber	Sets pharmaceutical price ceilings
FNS (National Health Fund)	Healthcare funding	Funds technology procurement for SUS

Legal Framework for Medical Procurement

The New Public Procurement Law (Law 14,133/2021)

Brazil's public procurement landscape underwent a fundamental transformation with the enactment of Law No. 14,133/2021 (Nova Lei de Licitações), which replaced the longstanding Law 8,666/1993. The new law has been fully applicable since December 2023 and introduces significant modernization to Brazil's procurement processes.

Key provisions relevant to medical device manufacturers:

• Mandatory transparency: All 5,568 municipalities, 27 states, and federal entities must publish contracting information on the PNCP (Portal Nacional de Contratacoes Publicas), creating a centralized, searchable record of all public procurement in Brazil.
• E-procurement mandate: Electronic procurement has been mandatory for federal purchases via Compras.gov.br since 2019 (Federal Decree 10,024/2019), and the new law reinforces this across all government levels.
• Competitive dialogue: A new modality allowing procuring entities to engage in structured dialogue with the market before issuing final specifications -- particularly relevant for innovative medical technologies.
• Framework agreements: Formalized as a procurement instrument, enabling multi-year, multi-entity purchasing arrangements -- increasingly used for medical devices.
• Performance-based contracts: New provisions allow for contracts tied to outcome metrics, opening possibilities for value-based procurement of medical devices.

Law 15,210/2025: SUS Diagnostic and Therapeutic Equipment

In September 2025, Brazil enacted Law No. 15,210/2025, which amended the procurement law specifically for SUS diagnostic and therapeutic equipment valued above BRL 50,000 (approximately USD 10,000). This legislation was designed to address longstanding complaints about SUS tender specifications that were either too rigid (favoring incumbents) or too loose (resulting in substandard equipment). The law introduces:

• Standardized technical specifications for major equipment categories
• Mandatory post-delivery performance verification
• Extended warranty requirements
• Training and technical support obligations for suppliers
• Specific evaluation criteria weighting clinical performance alongside price

Summary of Key Legislation

Legislation	Scope	Status
Law 14,133/2021	New Public Procurement Law	Fully applicable since December 2023
Law 15,210/2025	SUS diagnostic/therapeutic equipment >BRL 50,000	Enacted September 2025
Federal Decree 10,024/2019	Mandatory e-procurement for federal entities	In force since 2019
Law 14,313/2022	SUS payment for off-label drug uses (if CONITEC approves)	In force
Law 6,360/1976	General health surveillance law (ANVISA authority)	In force

CONITEC and Health Technology Assessment

What Is CONITEC?

The Comissao Nacional de Incorporacao de Tecnologias no SUS (National Commission for the Incorporation of Technologies in the SUS) is Brazil's national health technology assessment (HTA) body. Established in 2011 under the Ministry of Health, CONITEC is the gatekeeper for any new health technology -- including medical devices, pharmaceuticals, and procedures -- to be incorporated into SUS coverage.

For medical device manufacturers, CONITEC assessment is the critical step between ANVISA registration and actual public-sector market access. A device may be fully registered with ANVISA but will not be purchased by SUS unless CONITEC has evaluated and recommended its incorporation.

CONITEC Assessment Process

The CONITEC review process takes up to 180 days and follows a structured evaluation:

1. Submission: A technology sponsor (manufacturer, medical society, or Ministry of Health department) submits a dossier to CONITEC with clinical evidence, economic evaluation, and budget impact analysis.

2. Scientific evidence review: CONITEC evaluates safety and efficacy based on systematic reviews, clinical trials, and comparative studies. The standard of evidence expected correlates with device risk class and the severity of the condition treated.

3. Economic evaluation: CONITEC conducts cost-effectiveness analysis and budget feasibility assessment. This is not a formality -- Brazil's fiscal constraints mean that even clinically effective technologies can be rejected if the budget impact is deemed unsustainable.

4. Public consultation: During the review period, CONITEC opens a public consultation allowing patients, healthcare professionals, and industry to submit comments. This is a genuine consultation process, not a pro forma exercise.

5. Recommendation: CONITEC issues a recommendation to the Ministry of Health -- approve, do not approve, or defer for additional evidence.

6. Incorporation: If approved, the technology is incorporated into SUS through Clinical Protocols and Therapeutic Guidelines (CPTG), which define patient eligibility criteria, clinical pathways, and dosing/administration parameters.

Important Nuances for Device Manufacturers

• Class I and II devices are generally NOT subject to CONITEC assessment. Lower-risk devices follow simpler routes into SUS procurement, typically through standard tender processes where ANVISA registration and technical specifications are sufficient.
• Class III and IV devices -- particularly those involving new clinical applications, significant cost, or novel technology -- are more likely to require CONITEC evaluation.
• Oncology and autoimmune disease treatments receive priority attention from CONITEC, reflecting SUS epidemiological priorities.
• Rare diseases benefit from a faster CONITEC review pathway, acknowledging both the urgency and the smaller budget impact of therapies for rare conditions.
• Law 14,313/2022 expanded CONITEC's scope to include evaluation of off-label drug uses for SUS coverage, demonstrating the commission's growing influence.

CONITEC Assessment Criteria

Criterion	What CONITEC Evaluates
Scientific evidence	Safety, efficacy, and effectiveness based on clinical studies
Economic evaluation	Cost-effectiveness relative to existing SUS technologies
Budget feasibility	Projected budget impact on SUS at national scale
Equity	Impact on access disparities across regions and populations
Organizational impact	Implications for SUS infrastructure, training, and workflow

The SUS Procurement Process

Decentralized Procurement Architecture

SUS procurement is fundamentally decentralized. Federal, state, and municipal entities all procure independently within the legal framework set by Law 14,133/2021. Philanthropic and university hospitals that serve SUS patients also contract independently. This decentralization means there is no single "SUS procurement office" to approach -- manufacturers must navigate thousands of individual procuring entities.

Procurement Modalities

The New Public Procurement Law defines several modalities, each applicable based on the value and nature of the purchase:

Modality	Portuguese Name	Typical Use Case	Threshold
Electronic auction	Pregao eletronico	Most common for medical devices and supplies	Primary modality for standard devices
Competitive tender	Concorrencia	High-value, complex equipment	Large capital equipment
Price quotation	Tomada de precos	Medium-value purchases	Based on entity thresholds
Invitation	Convite	Smaller purchases	Limited number of invited bidders
Competitive dialogue	Dialogo competitivo	Innovation and technology procurement	New under Law 14,133/2021
Direct purchase	Dispensa de licitacao	Small-value transactions	Under BRL 8,000 (~$2,400)

Additional rules govern the process:

• Between BRL 8,000 and BRL 80,000 (~$2,400 to ~$16,000): at least three written price quotations are required.
• Framework agreements are increasingly used for recurring device needs, allowing a single competitive process to establish supply terms for multiple entities over multiple years.
• Integrity program requirements apply to large tenders above BRL 200 million, and an integrity program can serve as a tie-breaking criterion between otherwise equal bids.

Key E-Procurement Platforms

Compras.gov.br

Brazil's federal e-procurement portal, operated by the Ministry of Economy. Mandatory for all federal entity purchases, Compras.gov.br hosts electronic auctions (pregoes), manages supplier registration, and publishes all procurement notices. Since fall 2025, the platform publishes procurement data in the Open Contracting Data Standard (OCDS), making Brazilian federal procurement data more accessible to international analytics and monitoring.

PNCP (Portal Nacional de Contratacoes Publicas)

The national procurement portal centralizes data from all government levels -- federal, state, and municipal. Under Law 14,133/2021, all 5,570+ government entities must publish their contracting information on PNCP. For manufacturers, this is the single most important tool for market intelligence: you can identify who is buying what, at what volumes, at what prices, and on what timeline.

Banco de Precos em Saude (BPS)

The Health Price Database records purchase prices from both public and private healthcare transactions. BPS serves multiple purposes: it supports price research for tender preparation, provides reference pricing, and strengthens SUS negotiating power by creating price transparency. For device manufacturers, BPS data directly informs the ceiling prices used in public tenders.

SICAF (Sistema Integrado de Cadastramento de Fornecedores)

Brazil's supplier registration system. Foreign companies can register in SICAF -- a significant improvement over previous rules that required complex upfront documentation. Under Normative Instruction 10 (May 2020), a CNPJ (Brazilian tax ID) is only needed upon winning a bid, not at the registration stage. Sworn translation of foreign documents is only mandatory at the contract signing stage if a foreign bidder wins.

CATSER

Brazil's product coding system for medical supplies used in tenders. Proper CATSER coding is essential for manufacturers to ensure their products appear in relevant tender searches and specifications.

The Tendering Process Step by Step

A typical SUS electronic auction (pregao eletronico) for medical devices follows this sequence:

1. Needs assessment: The procuring entity identifies its requirements and develops technical specifications, often referencing CATSER codes and BPS reference prices.

2. Tender publication: The notice is published on Compras.gov.br and PNCP, including technical specifications, evaluation criteria, and deadlines.

3. Supplier qualification: Bidders submit documentation including ANVISA registration, tax compliance certificates, and product technical information. For foreign bidders, much of this can be submitted electronically.

4. Bid submission: Suppliers submit initial price proposals electronically.

5. Reverse auction: Qualifying bids enter a real-time, descending-price electronic auction. Bidders can see the current lowest price (without identifying competitors) and submit improved offers.

6. Adjudication: The lowest-priced compliant bid is preliminarily awarded.

7. Resource period: Losing bidders may challenge the result.

8. Contract execution: The winning bidder executes the supply contract. For foreign companies, this is where sworn translations and a legal representative in Brazil become mandatory.

Customs and Import Considerations

Medical devices imported into Brazil clear through one of four customs channels:

Channel	Action	Typical for Devices
Green	No inspection	Low-risk, well-known products
Yellow	Document review	Standard registered devices
Red	Physical inspection	New products, flagged shipments
Grey	Detailed inspection	Suspected irregularities

Clinical trial imports deserve special attention: clearing imported investigational devices through Brazilian customs can range from 4 weeks to over 5 months, depending on documentation completeness, product classification, and port of entry. Manufacturers planning clinical trials in Brazil should build substantial lead time into their logistics planning.

Pricing and Reimbursement in the Public System

How SUS Pricing Works

SUS does not operate a fee schedule for medical devices in the same way that some single-payer systems do. Instead, pricing is determined through the competitive tender process, informed by reference data:

• BPS reference prices serve as the starting point for tender ceiling prices.
• Competitive dynamics in the reverse auction typically drive final prices well below commercial (private-sector) prices.
• Domestic preference margins of 12-25% may apply to locally manufactured products, meaning a foreign manufacturer's bid must be significantly lower than a domestic competitor's to win.

CMED and Pharmaceutical Price Ceilings

While CMED (Camara de Regulacao do Mercado de Medicamentos) sets price ceilings specifically for pharmaceuticals, its methodology and reference pricing approach influence the broader SUS pricing environment. For combination products (drug-device combinations) and pharmaceutical products, CMED ceiling prices are a binding constraint.

Compulsory Licensing

Brazil maintains the ability to issue compulsory licenses for pharmaceuticals and health technologies under certain circumstances. In February 2026, the Brazilian Senate received a bill (Bill #160/2026) proposing compulsory licensing for tirzepatide (Mounjaro), and the Chamber of Deputies approved urgent consideration of the measure in March 2026. While compulsory licensing has not yet been formally invoked, the legislative push signals that the government is actively pursuing this mechanism to manage costs for high-priority treatments. While compulsory licensing has historically been applied to pharmaceuticals, the legal framework extends to health technologies more broadly, and device manufacturers should be aware of this risk for novel, high-cost technologies.

Priority Therapeutic Areas

SUS procurement prioritizes certain therapeutic areas, which directly affects the speed and likelihood of CONITEC assessment and the volume of subsequent procurement:

Priority Area	SUS Rationale
Oncology	High disease burden, significant unmet need
Autoimmune diseases	Growing prevalence, high treatment costs
Rare diseases	Smaller patient populations, faster CONITEC pathway
Cardiovascular	Leading cause of mortality in Brazil
Infectious diseases	Endemic tropical diseases, epidemic preparedness

Requirements for Foreign Suppliers

Regulatory Prerequisites

Before participating in any SUS tender, foreign medical device manufacturers must satisfy ANVISA's regulatory requirements:

• ANVISA registration: Required for all device classes (I through IV). There is no exemption for public procurement.
• B-GMP certification: Required for Class III and IV devices. Brazil recognizes MDSAP (Medical Device Single Audit Program) certificates, which can streamline this requirement for manufacturers already certified under MDSAP.
• Brazil Registration Holder (BRH): Mandatory for all foreign manufacturers. The BRH is a legal entity domiciled in Brazil that holds the device registration on behalf of the foreign manufacturer and serves as the primary point of contact with ANVISA.
• INMETRO certification: Required for certain product categories (electrical safety, electromagnetic compatibility, and other standards).

Tender Participation Requirements

Requirement	When Needed	Notes
ANVISA registration	Before bidding	Non-negotiable; device must be registered in Brazil
CNPJ (tax ID)	Upon winning bid	Not required at registration stage (NI 10/2020)
SICAF registration	Before bidding	Electronic; foreign companies can register
Legal representative in Brazil	For contract execution	Required to sign supply contract
Sworn translations	If foreign bidder wins	Only at contract signing, not at bid stage
Tax compliance certificates	Before bidding	Specific Brazilian tax clearances needed

Domestic Preference Margins

Brazil's procurement law provides preference margins for domestically manufactured products:

• Up to 12% for goods produced in Brazil that meet national content requirements.
• Up to 25% in specific sectors or regions targeted for industrial development.
• These margins effectively mean that a foreign manufacturer's bid must be 12-25% lower than a domestic competitor's to win on price alone.

For manufacturers considering local production, Brazil offers several incentives: the Manaus Free Trade Zone, state-level tax incentives for medical device manufacturing, and favorable treatment in public tenders. Several major device manufacturers (including some with European and US headquarters) have established Brazilian production facilities partly to capture these procurement advantages.

Language Considerations

While the Comprasnet platform is being gradually translated into English, the vast majority of tender documents, technical specifications, and legal requirements are in Portuguese. Manufacturers bidding on SUS tenders should have Portuguese-language capability in-house or through their Brazilian legal representative. Bid submissions in languages other than Portuguese are not accepted.

SUS Digital Transformation

Digital Health Strategy

Brazil's federal government has launched a comprehensive Digital Health Strategy aimed at modernizing SUS infrastructure. The SUS Digital Program is expanding digital services, improving connectivity across the system's 50,000+ facilities, and building the foundation for data-driven healthcare delivery.

Key digital initiatives affecting procurement:

• Health data interoperability: A major push to standardize health data across SUS facilities, enabling better demand forecasting and procurement planning.
• Telehealth integration: Expanded telehealth services create new procurement needs for remote monitoring devices, digital diagnostic tools, and connected health platforms.
• Open Contracting Data Standard: Since fall 2025, Compras.gov.br publishes procurement data in OCDS format, making the data machine-readable and internationally accessible.
• AI-powered procurement analytics: The Ministry of Health is developing artificial intelligence tools to analyze procurement patterns, identify inefficiencies, and support better purchasing decisions across the SUS network.

Implications for Device Manufacturers

The digital transformation of SUS creates both opportunities and challenges:

• Digital health devices (SaMD, connected devices, remote monitoring platforms) are increasingly relevant to SUS procurement, but may face novel regulatory and assessment pathways through both ANVISA and CONITEC.
• Open procurement data means manufacturers can conduct sophisticated competitive analysis -- but so can their competitors. Price transparency is increasing.
• AI-driven analytics may reduce opportunities for inflated margins while rewarding manufacturers who demonstrate clear value propositions.

Strategic Recommendations for Market Entry

For Manufacturers New to Brazil

1. Start with ANVISA registration early: The registration process can take 12-24 months depending on device class. Begin this process before developing your SUS procurement strategy, as registration is a prerequisite for everything else.

2. Choose your BRH carefully: Your Brazil Registration Holder is not just a regulatory agent -- they are your legal anchor in Brazil. Choose a partner with procurement experience and established relationships with SUS entities.

3. Map the procurement landscape using PNCP: Before investing in tender participation, use PNCP data to understand which entities buy your type of device, at what volumes, at what prices, and on what cycles. This intelligence is publicly available and underutilized by most foreign manufacturers.

4. Evaluate CONITEC requirements early: For Class III/IV devices, determine whether CONITEC assessment is likely required. If so, begin assembling the clinical and economic evidence dossier well in advance. The 180-day review clock starts when you submit, not when you decide to enter the market.

5. Consider local manufacturing: For manufacturers targeting significant SUS volume, the domestic preference margin (12-25%) is a powerful incentive to establish Brazilian production. Even assembly or packaging operations in Brazil can qualify for preferential treatment.

For Manufacturers Already Registered with ANVISA

6. Register on SICAF and monitor Compras.gov.br: These are your primary interfaces with the procurement system. Ensure your product catalog is properly coded in CATSER.

7. Build relationships with procuring entities: While procurement is competitively tendered, understanding the needs, specifications, and procurement cycles of key state and municipal health departments is invaluable. Many entities hold pre-tender market consultations -- attend these.

8. Develop competitive pricing models: SUS reverse auctions reward aggressive pricing. Understand your cost floor and develop pricing models that account for the domestic preference margin if competing against local manufacturers.

9. Prepare Portuguese-language documentation: All tender submissions must be in Portuguese. Invest in professional translation of technical specifications, IFUs, and quality documentation.

10. Monitor CONITEC agenda: Track what technologies CONITEC is evaluating in your therapeutic area. A competitor's CONITEC approval can reshape the SUS procurement landscape for your product category.

Emerging Trends (2026)

Several developments are reshaping SUS medical device procurement in 2026:

• Law 15,210/2025 implementation: The new law specific to SUS diagnostic and therapeutic equipment is being implemented across states and municipalities, standardizing technical specifications and post-delivery requirements. Manufacturers should expect more uniform tender requirements but also more rigorous performance verification.

• Compulsory licensing push: The February 2026 legislative proposal (Bill #160/2026) to enable compulsory licensing of tirzepatide signals a more assertive government posture on health technology pricing. While the bill is still advancing through Congress and compulsory licensing has not yet been formally invoked, the legislative momentum suggests this tool may be used more actively in the future. Device manufacturers with novel, high-cost technologies should monitor this development closely.

• Nova Industria Brasil (NIB) targets: Brazil's government has set a target to raise domestic health technology production from 45% to 50% by 2026 and 70% by 2033. The BNDES SUS Suppliers program, with a R$500 million budget through 2028, offers streamlined credit to national manufacturers with a R$10 million minimum threshold. These initiatives signal a clear industrial policy direction that will progressively favor local production over imports.

• Biosimilar and generic device push: Politically and economically, Brazil supports domestic alternatives to imported health technologies. This creates both competition for foreign manufacturers and potential partnership opportunities with Brazilian companies.

• Framework agreement expansion: Multi-year, multi-entity framework agreements are becoming the preferred vehicle for high-volume device procurement. These agreements offer manufacturers predictable demand but require competitive pricing over longer horizons.

• Digital procurement maturity: The migration to OCDS data publication and AI-powered analytics is making SUS procurement more transparent, more data-driven, and more efficient -- which generally favors manufacturers with strong value propositions and competitive pricing over those relying on information asymmetry.

• Value-based procurement interest: While still early, there is growing interest within the Ministry of Health in moving beyond lowest-price-wins toward value-based procurement criteria. The competitive dialogue modality in Law 14,133/2021 enables this, and pilot programs are underway for certain device categories.

Practical Checklist

Use this checklist when preparing to enter the SUS medical device procurement market:

Regulatory Foundation

• ANVISA registration obtained or in progress
• B-GMP certification secured (Class III/IV) or MDSAP certificate available
• Brazil Registration Holder (BRH) appointed
• INMETRO certification obtained (if applicable to your product category)

Procurement Readiness

• SICAF registration completed
• Products properly coded in CATSER
• Portuguese-language technical documentation prepared
• Legal representative in Brazil identified for contract execution
• Pricing model developed that accounts for domestic preference margins

CONITEC Assessment (if applicable)

• Determined whether your device requires CONITEC evaluation
• Clinical evidence dossier assembled (systematic reviews, clinical trials)
• Economic evaluation prepared (cost-effectiveness analysis)
• Budget impact analysis developed
• Public consultation strategy prepared

Market Intelligence

• PNCP data analyzed for your product category
• BPS reference prices reviewed
• Key procuring entities identified (federal, state, municipal)
• Procurement cycles and timelines mapped
• Competitor landscape assessed

Operational

• Portuguese-language capability secured (in-house or through representative)
• Logistics and customs clearance process understood
• Distribution strategy defined (direct, through distributor, or local manufacturing)
• Post-delivery support and training capabilities established (required under Law 15,210/2025)

Key Takeaways

SUS is enormous but decentralized. The system covers 215+ million people across 50,000+ facilities, but procurement happens at thousands of individual entities. There is no single door to knock on -- manufacturers must approach the market systematically using PNCP data and local relationships.

Law 14,133/2021 modernized everything. The new procurement law, fully applicable since December 2023, introduces e-procurement mandates, competitive dialogue, framework agreements, and transparency requirements that reshape how SUS buys medical devices. Law 15,210/2025 adds specific requirements for diagnostic and therapeutic equipment above BRL 50,000.

CONITEC is the gatekeeper for public coverage. For higher-risk devices, CONITEC assessment (up to 180 days) is the bridge between ANVISA registration and actual SUS procurement. Manufacturers must invest in clinical and economic evidence to pass this gateway.

Foreign suppliers can compete, but face structural headwinds. The domestic preference margin (12-25%), Portuguese language requirements, and need for a local legal representative create barriers. However, eased registration rules (CNPJ only upon winning, sworn translations only at contract signing) have lowered the threshold for participation.

Digital transformation is accelerating transparency. Open procurement data, AI-powered analytics, and the SUS Digital Program are making the market more data-driven. Manufacturers who leverage this data -- and whose products demonstrate clear value -- will be best positioned.

Price competition is intense. Reverse auctions, reference pricing via BPS, and the government's willingness to use compulsory licensing all point to a procurement environment where cost containment is a primary driver. Manufacturers need sophisticated pricing strategies and, for large volumes, should seriously evaluate local manufacturing to capture preference margins.